HK1080846A1 - Benzoxazine derivatives as 5-ht6 modulators and uses thereof - Google Patents

Benzoxazine derivatives as 5-ht6 modulators and uses thereof

Info

Publication number
HK1080846A1
HK1080846A1 HK06100802.2A HK06100802A HK1080846A1 HK 1080846 A1 HK1080846 A1 HK 1080846A1 HK 06100802 A HK06100802 A HK 06100802A HK 1080846 A1 HK1080846 A1 HK 1080846A1
Authority
HK
Hong Kong
Prior art keywords
modulators
benzoxazine derivatives
benzoxazine
derivatives
Prior art date
Application number
HK06100802.2A
Other languages
English (en)
Inventor
Jacob Berger
Robin Douglas Clark
Shu-Hai Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1080846A1 publication Critical patent/HK1080846A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK06100802.2A 2002-05-13 2006-01-18 Benzoxazine derivatives as 5-ht6 modulators and uses thereof HK1080846A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37800302P 2002-05-13 2002-05-13
PCT/EP2003/004671 WO2003095434A1 (en) 2002-05-13 2003-05-05 Benzoxazine derivatives as 5-ht6 modulators and uses thereof

Publications (1)

Publication Number Publication Date
HK1080846A1 true HK1080846A1 (en) 2006-05-04

Family

ID=29420358

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06100802.2A HK1080846A1 (en) 2002-05-13 2006-01-18 Benzoxazine derivatives as 5-ht6 modulators and uses thereof

Country Status (37)

Country Link
US (4) US6867204B2 (xx)
EP (1) EP1506179B1 (xx)
JP (1) JP4307377B2 (xx)
KR (1) KR100636475B1 (xx)
CN (1) CN100429206C (xx)
AR (1) AR039988A1 (xx)
AT (1) ATE316523T1 (xx)
AU (1) AU2003233231B2 (xx)
BR (1) BRPI0310032B8 (xx)
CA (1) CA2485136C (xx)
DE (1) DE60303376T2 (xx)
DK (1) DK1506179T3 (xx)
EA (1) EA009982B1 (xx)
EC (1) ECSP045420A (xx)
EG (1) EG25683A (xx)
ES (1) ES2256744T3 (xx)
GT (1) GT200300108A (xx)
HK (1) HK1080846A1 (xx)
HR (1) HRP20041030B1 (xx)
IL (1) IL164928A0 (xx)
JO (1) JO2413B1 (xx)
MA (1) MA27118A1 (xx)
MX (1) MXPA04011254A (xx)
MY (1) MY139612A (xx)
NO (1) NO329380B1 (xx)
NZ (1) NZ536230A (xx)
PA (1) PA8573501A1 (xx)
PE (1) PE20040757A1 (xx)
PL (1) PL211057B1 (xx)
PT (1) PT1506179E (xx)
RS (1) RS51042B (xx)
TN (1) TNSN04225A1 (xx)
TW (1) TWI258479B (xx)
UA (1) UA76877C2 (xx)
UY (1) UY27803A1 (xx)
WO (1) WO2003095434A1 (xx)
ZA (1) ZA200408783B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1408976B3 (en) 2001-07-20 2010-08-25 Psychogenics Inc. Treatment for attention-deficit hyperactivity disorder
WO2003080580A2 (en) 2002-03-27 2003-10-02 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
ATE316523T1 (de) * 2002-05-13 2006-02-15 Hoffmann La Roche Benzoxazinderivate als 5-ht6-modulatoren und deren verwendungen
CN100390157C (zh) * 2002-11-08 2008-05-28 弗·哈夫曼-拉罗切有限公司 取代的苯并嗪酮及其用途
CN1826322B (zh) 2003-07-22 2012-04-18 艾尼纳制药公司 用于预防和治疗相关病症而作为5-ht2a血清素受体调节剂的二芳基和芳基杂芳基脲衍生物
CA2547764A1 (en) 2003-12-09 2005-06-30 F.Hoffmann-La Roche Ag Benzoxazine derivatives and uses thereof
KR100843053B1 (ko) * 2004-01-16 2008-07-01 에프. 호프만-라 로슈 아게 중추 신경계 질환의 치료를 위한 5-하이드록시트립트아민수용체(5-ｈｔ)의 조절제로서1-벤질-5-피페라진-1-일-3,4-다이하이드로-1ｈ-퀴나졸린-2-온 유도체 및 각각의1ｈ-벤조(1,2,6)티아다이아진-2,2-다이옥사이드 및1,4-다이하이드로-벤조(ｄ)(1,3)옥사진-2-온 유도체
BRPI0510642A (pt) * 2004-05-05 2007-11-20 Hoffmann La Roche arilsulfonil benzodioxanos úteis para modulação do receptor de 5-ht6, do receptor de 5ht2a ou ambos
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
US7378415B2 (en) * 2004-09-30 2008-05-27 Roche Palo Alto Llc Benzoxazine and quinoxaline derivatives and uses thereof
NZ553848A (en) * 2004-09-30 2010-01-29 Hoffmann La Roche Benzoxazine and quinoxaline derivatives and their use in treating diseases associated with the central nervous system
CA2582273C (en) * 2004-09-30 2013-10-29 Douglas William Bonhaus Compositions and methods for treating cognitive disorders using serotonin receptor antagonists
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
AR078770A1 (es) * 2009-10-27 2011-11-30 Elara Pharmaceuticals Gmbh Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas.
KR101293384B1 (ko) * 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
US9403800B2 (en) * 2012-01-24 2016-08-02 Chemregen, Inc. Compounds for inhibition of cancer cell proliferation
US10087151B2 (en) 2014-01-09 2018-10-02 The J. David Gladstone Institutes, A Testimentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds
AU2016276966A1 (en) 2015-06-12 2018-01-18 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of REM sleep behavior disorder
TW201720439A (zh) 2015-07-15 2017-06-16 Axovant Sciences Gmbh 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1029479C (zh) * 1989-11-08 1995-08-09 山之内制药株式会社 新型苯并噁嗪衍生物的制备方法
US5492914A (en) * 1994-07-28 1996-02-20 Syntex (U.S.A.) Inc. 2-(1-azabicyclo[2.2.2]oct-3 s-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[DE]is[2.2.2]oct-3's-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1h-benz [DE]isoquinolin-1-one and individual stereoisomers thereof
GB9507203D0 (en) 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
BR9809092A (pt) 1997-04-18 2002-01-22 Smithkline Beecham Plc Derivados de indol tendo atividade combinada de antagonista de receptor de 5ht1a, 5ht1b e 5ht1d
HUP0003073A3 (en) 1997-07-11 2002-10-28 Smithkline Beecham Plc Benzenesulfonamide derivatives, process for producing them and their use as medicines
CA2297825C (en) * 1997-07-25 2006-03-14 H. Lundbeck A/S Indole and 2,3-dihydroindole derivatives, their preparation and use
GB9801392D0 (en) 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
AU765317C (en) * 1998-06-19 2004-05-20 H. Lundbeck A/S 4,5,6 and 7-indole and indoline derivatives, their preparation and use
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
SI1212320T1 (en) * 1999-08-23 2005-10-31 Solvay Pharmaceuticals B.V. Phenylpiperazines as serotonin reuptake inhibitors
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
EP1255743A1 (en) 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa
ATE316523T1 (de) * 2002-05-13 2006-02-15 Hoffmann La Roche Benzoxazinderivate als 5-ht6-modulatoren und deren verwendungen

Also Published As

Publication number Publication date
EA200401455A1 (ru) 2005-06-30
UA76877C2 (uk) 2006-09-15
KR100636475B1 (ko) 2006-10-18
BRPI0310032B8 (pt) 2021-05-25
DK1506179T3 (da) 2006-06-06
NZ536230A (en) 2007-05-31
BRPI0310032B1 (pt) 2019-01-08
ZA200408783B (en) 2005-12-28
HRP20041030A2 (en) 2005-06-30
IL164928A0 (en) 2005-12-18
UY27803A1 (es) 2003-11-28
TNSN04225A1 (fr) 2007-03-12
MA27118A1 (fr) 2004-12-20
ATE316523T1 (de) 2006-02-15
EP1506179B1 (en) 2006-01-25
DE60303376T2 (de) 2006-11-16
MY139612A (en) 2009-10-30
NO20044665L (no) 2004-12-03
CN100429206C (zh) 2008-10-29
JO2413B1 (en) 2007-11-11
TWI258479B (en) 2006-07-21
CA2485136A1 (en) 2003-11-20
US20130123251A1 (en) 2013-05-16
ES2256744T3 (es) 2006-07-16
PT1506179E (pt) 2006-06-30
CN1653054A (zh) 2005-08-10
MXPA04011254A (es) 2005-01-25
PE20040757A1 (es) 2004-11-06
JP4307377B2 (ja) 2009-08-05
AU2003233231A1 (en) 2003-11-11
US20050130962A1 (en) 2005-06-16
EA009982B1 (ru) 2008-04-28
EG25683A (en) 2012-05-16
EP1506179A1 (en) 2005-02-16
ECSP045420A (es) 2005-01-03
US6867204B2 (en) 2005-03-15
RS51042B (sr) 2010-10-31
JP2005530774A (ja) 2005-10-13
AR039988A1 (es) 2005-03-09
PL211057B1 (pl) 2012-04-30
AU2003233231B2 (en) 2009-02-26
US20030232825A1 (en) 2003-12-18
DE60303376D1 (de) 2006-04-13
TW200400188A (en) 2004-01-01
PA8573501A1 (es) 2003-12-10
CA2485136C (en) 2011-12-20
PL374019A1 (en) 2005-09-19
NO329380B1 (no) 2010-10-04
BR0310032A (pt) 2005-02-15
RS97004A (xx) 2006-10-27
US20090325950A1 (en) 2009-12-31
WO2003095434A1 (en) 2003-11-20
KR20040106538A (ko) 2004-12-17
GT200300108A (es) 2004-03-15
US8377931B2 (en) 2013-02-19
HRP20041030B1 (hr) 2013-03-31

Similar Documents

Publication Publication Date Title
HK1080846A1 (en) Benzoxazine derivatives as 5-ht6 modulators and uses thereof
AU2003266321A1 (en) Tetrahydropyrimidine-2-one derivatives and their uses
IL175817A0 (en) Benzoxazine derivatives and uses thereof
HK1083497A1 (en) 2,4-Substituted indoles and their use as 5-ht6 modulators
AP2004003110A0 (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
AU2003249909A1 (en) Phenoxypropenylphenyl derivatives and their use as herbicides
IL185549A0 (en) Pyrimidine derivatives and their use as cb2 modulators
IL172894A0 (en) Indol-6-sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators
HK1083500A1 (en) 2,7-Substituted indoles and their use as 5-ht6 modulators
AU2003236135A1 (en) Aralkyl-alcohol peiperazine derivatives and their uses as antidepressant
IL172891A0 (en) Indol-5-yl-sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators
IL163868A0 (en) Hermiasterlin derivatives and uses thereof
HK1088327A1 (en) Thiadiazine derivatives and use thereof as positive ampa receptor modulator
AU2003292422A1 (en) Oxazolidinone derivatives and their use as antibacterial agents
AU2003289222A1 (en) Benzomorpholine derivatives
GB0316910D0 (en) Fluorocombretastatin and derivatives thereof
AU2003900495A0 (en) Aroylhydrazone derivatives and therapeutic uses thereof
SI1506179T1 (sl) Derivati benzoksazina kot modulatorji 5-ht6 in njihova uporaba
AU2003205963A1 (en) Azaphenylalanine derivatives and their use as antithrombotic agents
AU2003215095A1 (en) Stand up diaper
HUP0600155A2 (en) Early inflorescence-preferred regulatory elements and uses thereof
GB0307231D0 (en) 7-Nitroindoline derivatives and their uses
EP1499338A4 (en) 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSENES-17-ONE AND 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSTAN-17-ONE AND THEIR DERIVATIVES
GB0223915D0 (en) Benzofuran derivatives formulations and uses thereof
AU2003240427A1 (en) Novel benzimidazol-2-one derivatives and their use

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20230504